The drawn-out takeover bid by Swiss pharma giant Roche of Genentech has “gone hostile,” according to the website FiercePharma.

Roche has been haggling since July with Genentech’s board over the share price it will pay for the San Francisco-based biotech, which has a 500-employee plant in Oceanside that manufactures its best-selling cancer drug Avastin. It finally lost patience Friday, and not only went hostile, but lowered its offer, according to the FiercePharma post. Roche dropped its bid from $44 billion to $42 billion.

In September, we wrote about how the employees might be affected by the takeover. And since, we’ve been keeping track of the takeover bid.


Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.